We also tested the combinatory effect of actinomycin D with the p53-independent chemotherapeutic agent suberoylanilide hydroxamic acid, SAHA, which is now in clinical trials for neuroblastomas treatment [26]. Here, TP53 is linked to neuroblastoma.